Compare BMR & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BMR | XLO |
|---|---|---|
| Founded | 2009 | 2016 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.4M | 41.8M |
| IPO Year | 2023 | 2021 |
| Metric | BMR | XLO |
|---|---|---|
| Price | $1.97 | $0.65 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.00 |
| AVG Volume (30 Days) | 87.6K | ★ 563.4K |
| Earning Date | 08-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $3,131,000.00 | ★ $31,804,000.00 |
| Revenue This Year | $21.21 | $589.60 |
| Revenue Next Year | N/A | $38.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 5.96 | ★ 588.40 |
| 52 Week Low | $1.86 | $0.62 |
| 52 Week High | $6.59 | $1.70 |
| Indicator | BMR | XLO |
|---|---|---|
| Relative Strength Index (RSI) | 37.57 | 32.76 |
| Support Level | $2.18 | $0.64 |
| Resistance Level | $2.21 | $0.73 |
| Average True Range (ATR) | 0.17 | 0.04 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 8.08 | 15.89 |
Beamr Imaging Ltd is a video technology and image science software company. It is an innovator of video encoding, transcoding, and optimization solutions that enable high quality, performance, and unmatched bitrate efficiency for video and images. The company is conducted through one operating segment, the optimization technology for video and photo compression. The company operates in Israel, the United States, and the rest of the world, it derives a majority of its revenue from the United States.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.